The importance of real-life research in respiratory medicine: Manifesto of the Respiratory Effectiveness Group

TY - JOUR

T1 - The importance of real-life research in respiratory medicine

T2 - Manifesto of the Respiratory Effectiveness Group

AU - the Respiratory Effectiveness Group Collaborators

AU - Roche, Nicolas

AU - Anzueto, Antonio

AU - Anticevich, Sinthia Bosnic

AU - Kaplan, Alan

AU - Miravitlles, Marc

AU - Ryan, Dermot

AU - Soriano, Joan B.

AU - Usmani, Omar

AU - Papadopoulos, Nikolaos G.

AU - Canonica, G. Walter

AU - Agache, Ioanna

AU - Barnes, Peter

AU - Bateman, Eric

AU - Behr, Jürgen

AU - Bjermer, Leif

AU - Blakey, John

AU - Bouros, Demosthenes

AU - Bousquet, Jean

AU - Brown, Kevin

AU - Brusselle, Guy

AU - Calderon, Moises

AU - Campbell, Jon

AU - Cardell, Lars Olaf

AU - Castro-Rodriguez, Jose A.

AU - Chaudhuri, Nazia

AU - Chavannes, Niels

AU - Corte, Tamera

AU - Costello, Richard

AU - Cottin, Vincent

AU - Custovic, Adnan

AU - Dandurand, Ronald

AU - Diamant, Zuzana

AU - Demoly, Pascal

AU - Ducharme, Francine

AU - Feleszko, Wojciech

AU - Fitzgerald, Mark

AU - Fokkens, Wytske

AU - Freeman, Daryl

AU - Gaga, Mina

AU - Geiser, Thomas

AU - Glaspole, Ian

AU - Gouder, Caroline

AU - Haughney, John

AU - Heaney, Liam

AU - Hedlin, Gunilla

AU - Hellings, Peter

AU - Hoe, Teoh Oon

AU - Israel, Elliot

AU - Jartti, Tuomas

AU - Jones, Mark

N1 - Funding Information: This document has been Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization. The authors wish to thank the Respiratory Effectiveness Group Team (Michael Walker, CEO and Supporter Liaison, Naomi Launders, Senior Scientific Researcher and Sarah Lucas, Researcher) and Oversight Committee (Keith Allan, Trevor Lambert and Nick May). Funding Information: Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Sanofi, Sandoz, 3M, Zambon and Trudell, outside the submitted work. A. Anzueto reports personal fees for consultancy from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Bosnic Anticevich reports personal fees for advisory board work from TEVA, personal fees for consultancy from GSK and MEDA, grants from TEVA, personal fees for lectures from TEVA, GSK and AstraZeneca, personal fees for manuscript preparation from MEDA, personal fees for educational activities from GSK, outside the submitted work. A. Kaplan reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Pfizer, personal fees from Covis, GSK, Sanofi, Merck Frosst, Novartis, Purdue, Teva, Trudel, Novo Nordisk and Griffols, during the conduct of the study. M. Miravitlles reports personal fees for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, personal fees for consultancy from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, grants from GlaxoSmithKline and Grifols, outside the submitted work. D. Ryan reports personal fees for advisory board work from GSK, BI and Novartis, personal fees for lectures and advisory board work from AZ, personal fees for lectures and meeting attendance from MEDA, outside the submitted work; and was previous president of REG, current vice president of REG and consultant strategic medical adviser, Optimum Patient Care. J.B. Soriano participated in speaking activities, advisory committees and consultancies during the period 2014–2019 sponsored by: Almirall, AstraZeneca, Boehringer Ingelheim, Chest, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. O. Usmani reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, grants from GlaxoSmithKline and Edmond Pharma, personal fees from Aerocrine, Napp, Mundipharma, Sandoz, Takeda, Zentiva and Cipla, outside the submitted work. N. Papadopoulos reports personal fees for advisory board work and lectures from Novartis, Nutricia, HAL, MENARINI/FAES FARMA and MYLAN/MEDA, personal fees for lectures from SANOFI, BIOMAY, MSD, ASIT BIOTECH and Boehringer Ingelheim, personal fees for advisory board work from AstraZeneca and GSK, grants from Gerolymatos International SA and Capricare, outside the submitted work. G.W. Canonica has nothing to disclose.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85072390937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072390937&partnerID=8YFLogxK

U2 - 10.1183/13993003.01511-2019

DO - 10.1183/13993003.01511-2019

M3 - Editorial

C2 - 31537655

AN - SCOPUS:85072390937

SN - 0903-1936

VL - 54

JO - The European respiratory journal

JF - The European respiratory journal

IS - 3

M1 - 1901511

ER -